The management of neuropathic pain remains very challenging and very much an art. Despite the publication of multiple consensus guidelines on the management of neuropathic pain, a significant subpopulation of patients with neuropathic pain are not afforded adequate relief, employing various treatment algorithms with conventional pharmacologic therapeutic strategies. First-line agents for the treatment of neuropathic pain include: tricyclic antidepressants, selective serotonin/norepinephrine re-uptake inhibitors, calcium channel α2-δ ligands and, in certain cases of focal neuropathic pain, a lidocaine patch. Novel analgesics under development may include: purinergic receptor modulators, cannabinoid receptor modulators, neurokinin-1 (NK-1) receptor modulators, glial modulators, rostral ventral medulla 'on-cell' modulators, chemokine receptor modulators, toll-like receptor modulators, modulators of tetrahydrobiopterin synthesis, and/or chemically re-engineered conotoxins. It is hoped that future agents and/or combinations of agents may be helpful to this refractory subpopulation.
Neuropathic pain (NP) originates as a result of a lesion or disease (e.g., diabetes, herpes zoster, HIV infection, chemotherapy or surgery) pertaining to the somatosensory system. 1 NP can be classified as peripheral or central depending on where the lesion/disease is located. 2 The clinical presentation of NP includes both positive and negative sensory phenomena: e.g., pain and lack of sensation.
The presence of NP can be categorized in three groups depending on the certainty of its existence: the 'definite' and 'probable' levels indicate that the presence of NP is established, and the 'possible' level does not confirm the existence of this condition. 2 These levels are assigned by using the NP grading system, which consists of four criteria:
• pain with a distinct neuroanatomically plausible distribution;
• a history suggestive of a relevant lesion or disease affecting the peripheral or central somatosensory system;
• demonstration of the distinct neuroanatomically plausible distribution by at least one confirmatory test; and
• demonstration of the relevant lesion or disease by at least one confirmatory test.
If all of the four criteria stated above are met, the diagnosis of definite NP is made. Probable NP is present if the first, second and either the third or fourth criteria are met. The diagnosis of possible NP requires the first two criteria without the third or fourth. If the patient fails to exhibit the criteria for these three levels, the NP is considered as absent. 2 Commonly used recent screening tools to identify NP include Leeds assessment of neuropathic symptoms and signs, Douleur neuropathique 4 questions, Neuropathic questionnaire, painDETECT, and ID Pain. Bennett et al.
conducted research in 2007 investigating these five screening tools and noted that three symptomatic items ('prickling, tingling, pins and needles', 'electric shocks or shooting', and 'hot or burning') were found in all tools.
Also 'numbness' and 'pain evoked by light touching' were present in 80 % of the tools investigated in Bennett et al.'s research. 3 Quantitative sensory testing (QST) is one of the tools useful in evaluating sensation, focusing on the definition of the stimulus properties, the quantity of sensory intensity and the quality of sensation. QST, skin biopsies, imaging electrodiagnostic studies, pertinent ancillary data and the symptoms exhibited by the patient should be studied while treating the NP. The clinician should consider a 'rational polypharmacotherapy' for the case if a single agent is not enough to relieve the NP. 4 The illness or injury preceding NP may present itself with both medical and psychiatric comorbidities, disturbing the diagnosis and assessment of NP. 
Treatment of Neuropathic Pain
The treatment of NP is difficult because less than half of patients receive satisfactory pain relief (>30 % reduction) while side effects are common.
Although being treated with multiple medications, studies have shown that NP patients continue to have pain of moderate severity. 6 O'Connor states that this inefficacy may result in part from inappropriate medication prescription or use of insufficient dosage in treating these patients. The
Neuropathic Pain Special Interest Group (NeuPSIG) outlined three lines of medications to treat NP. 7 Combinations of medications appear to provide greater pain relief compared with monotherapy, although there is not a great deal of evidence surrounding combination therapy. There are also non-pharmacologic approaches to the treatment of NP which include:
physical medicine approaches, behavioral approaches, interventional approaches, surgical approaches, and neuromodulation approaches.
Medication Management of Neuropathic PainCurrent Recommendations
The The first-line agents for NP recommended by the IASP NeuPSIG included:
tricyclic antidepressants (TCAs), calcium channel α2-δ ligands, selective serotonin/norepinephrine re-uptake inhibitors (SNRIs) and topical lidocaine (for localized peripheral NP). 7 Opioids and tramadol were recommended as second-line agents except in selected circumstances, such as the treatment of acute NP, episodic exacerbations of severe NP and neuropathic cancer pain and during the titration of a first-line agent in patients with severe pain. 7 The CPS guidelines recommended TCAs and calcium channel α2-δ ligands as first-line medications. 9 SNRIs and topical lidocaine (for localized peripheral NP) were recommended as second-line medications and opioid analgesics and tramadol were recommended as third-line analgesic agents for the treatment of NP. 9 In 2010, the EFNS updated its guidelines. 10 Recommendations for first-line a simplistic yet clinically useful categorization divides them into TCAs, SNRIs, selective serotonin re-uptake inhibitors (SSRIs) and selective norepinephrine (noradrenalin) re-uptake inhibitors (NRIs or NARIs).
Tricyclic Antidepressants
The TCAs can be divided into amines and their demethylated secondary amine derivatives. The tertiary amine TCAs include the following:
• amitriptyline (Elavil ® );
• imipramine (Tofranil ® );
• trimipramine (Surmontil ® );
• clomipramine (Anafranil ® ); and
The secondary amine TCAs include the following:
• nortriptyline (Pamelor ® );
• desipramine (Norpramin ® );
• protriptyline (Vivactil ® ); and
• amoxapine (Asendin ® ). TCAs may exhibit a wide range of adverse effects and differ significantly as regards which TCAs have which effects. Adverse effects include:
anticholinergic effects (desipramine has the least anticholinergic effects), antihistaminergic effects (doxepin has the most potent antihistaminergic effects), α-1 adrenergic receptor blockade (e.g., orthostatic hypotension), and cardiac effects (increasing intraventricular conduction, prolonged QT interval, prolonged through the atrioventricular node). Other side effects of TCAs include orthostatic hypotension as well as those related to their anticholinergic activity including urinary retention, dry mouth, and constipation. Cardiac toxicity has been described as a possible side effect of TCAs; sinus and ventricular arrhythmias were noted in patients with a history of coronary artery disease (CAD) and depression who were on nortriptyline. 17 A large review study has shown some cardiac complications, including myocardial infarction, with doses more than 100 mg/day, but did not demonstrate adverse cardiac outcomes in patients who were on a regimen of less than 100 mg/day. 18 One of the advantages of TCAs is that they are taken once daily and are not expensive. When committing a patient with NP to treatment with TCAs, the lowest effective dose should be used.
In patients with a history of arrhythmias and CAD, TCAs should be avoided Although the role of SSRIs in providing effective analgesia is uncertain, it appears limited at best.
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Selective Serotonin/Norepinephrine Re-uptake Inhibitors
Duloxetine and venlafaxine are antidepressants with both serotonergic and noradrenergic re-uptake inhibiting properties (SNRIs). The former has been extensively studied and used in the treatment of diabetic neuropathy and has been demonstrated to be efficacious over placebo in multiple RCTs that showed doses of 60 and 120 mg/day to be both safe and effective. [25] [26] [27] The side effect profile of duloxetine seems to be more favorable than TCAs, especially with respect to anticholinergic and cardiac side effects. Nausea has been reported as one of the common side effects and is reduced by lowering the dose. 28 For many patients, nausea is self-limited and resolves within the first several weeks of usage. Duloxetine has been extensively studied in patients with diabetic peripheral neuropathy, fibromyalgia, musculoskeletal back pain, and osteoarthritis, and is Food and Drug Administration (FDA)-approved for all four indications. Venlafaxine has been effective in the treatment of diabetic painful neuropathy (DPN) and other polyneuropathies, except PHN. 7 A small subset of patients demonstrated cardiac conduction abnormalities; thus precautions should be taken in patients with a history of cardiac pathologies. Venlafaxine should be tapered rather than abruptly discontinued because of a withdrawal syndrome that has been reported. 29 At doses less than 150 mg/day, venlafaxine behaves more like a serotonergic-specific re-uptake inhibitor or SSRI; at doses above 150 mg, it behaves more like an SNRI agent and pain relief is more likely to occur with doses of 150 mg/day or greater. Venlafaxine is not FDA-approved for any pain indication.
Calcium Channel Alpha-2 Delta Ligands
Gabapentin and pregabalin are calcium channel α2-δ ligands. The mechanism of action of each of these is through their ability, in an excited neuron, to reduce calcium influx into the neuron with subsequent reduction of neurotransmitter release such as substance P, glutamate and norepinephrine. [30] [31] [32] [33] [34] [35] [36] Although calcium channel ligands can lead to dose-dependent somnolence and dizziness, as well as weight gain and peripheral edema, they have few drug-drug interactions. Their dose must be lowered in patients with renal insufficiency. 7 Another advantage of pregabalin is that it has some anxiolytic effects, which is frequently helpful with concurrent anxiety seen in patients with NP. 37 Gabapentin is FDA-approved for PHN. Pregabalin is FDA-approved for PHN as well as DPN and fibromyalgia.
Gabapentin exhibits non-linear pharmacokinetics. That is, as doses are increased, less of the drug is absorbed and therefore much of it is excreted in the urine rather than being clinically effective. It should be introduced to a patient in a low-dose fashion and increased until analgesia has been achieved or side effects are experienced. The maximum recommended dosage of gabapentin is 3,600 mg/day for DPN and 1,800 mg/day for PHN and its effect can be seen as soon as two weeks, although an adequate therapeutic trial can take up to several months. 1 Gabapentin is now available in extended-release formulations.
Although pregabalin and gabapentin have identical mechanisms of action, pregabalin has improved pharmacokinetics and linear bioavailability, both of which are significant advantages. Its onset of analgesia is faster than gabapentin, secondary to its shorter titration period. The current recommendations are titration up to 300 mg/day divided into three doses for DPN and up to 600 mg/day divided into three doses for PHN. 1 For maintenance treatment it is generally dosed twice a day (bid). However, some elderly patients or those patients more sensitive to medication may prefer taking a lower dose three times a day (tid). The doses for both gabapentin and pregabalin should be reduced in patients with chronic kidney disease.
Topical Lidocaine
The 
N-Methyl D-Aspartate Receptor Antagonists
Inconsistent outcomes for the use of memantine and dextromethorphan have been observed; however, they have been occasionally tried with patients who failed other therapies. 7, 12 Dextromethorphan is effective in a dose-related fashion in selected patients with DPN but not in PHN. 
Combination Therapy
The use of 'rational polypharmacy' in pain management has not been particularly well studied. Gilron et al. have shown that the combination of gabapentin and morphine achieved better analgesia at lower doses of each drug than either as a single agent for NP 48 and that the combination of gabapentin and nortriptyline seems more efficacious than either drug administered as monotherapy for NP. 
Summary
NP is an extremely complex and challenging problem. Despite the availability and employment of multiple treatment guidelines/algorithms, a significant subpopulation of patients with NP still do not achieve adequate analgesia. At least from the standpoint of pharmacologic approaches to the treatment of NP, this is probably due in part to available agents not significantly affecting important potential therapeutic targets.
It is hoped that the development of novel therapeutic agents may expand the achievement of satisfactory analgesia to a larger population of patients currently suffering with NP. n
